Elizabeth J Siembida1, Bryce B Reeve2, Brad J Zebrack3, Mallory A Snyder4, John M Salsman5. 1. Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, Maryland, USA. 2. Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina, USA. 3. School of Social Work, University of Michigan, Ann Arbor, Missouri, USA. 4. Office of Research and National Laboratories, The University of Chicago, Illinois, Chicago, USA. 5. Department of Social Sciences and Health Policy, Wake Forest School of Medicine & the Wake Forest Baptist Comprehensive Cancer Center, North Carolina, Winston-Salem, USA.
Abstract
OBJECTIVE: Our knowledge of symptom burden and functioning among adolescent and young adult (AYA; diagnosed ages 15-39) cancer survivors has been hindered by variability in health-related quality of life (HRQOL) measurement associated with developmental and disease heterogeneity among AYAs. We aimed to examine the variability in domain-specific aspects of HRQOL as a function of cancer type and developmental stage to clarify commonalities and differences using the NIH Patient-Reported Outcome Measurement Information System® . METHODS: Five hundred seventy-two AYAs were recruited by an online research panel using stratified sampling (treatment status: on vs. off; developmental stage: adolescents, emerging adults, young adults). Participants completed questionnaires that included sociodemographic characteristics, clinical history, and the adult version of the Patient-Reported Outcomes Measurement Information System® -29 (PROMIS-29). Generalized linear models were run for each HRQOL domain and included treatment status, developmental stage, and cancer type (hematologic vs. solid tumor) and their interactions as independent variables. RESULTS: There were no significant differences in any HRQOL domain by cancer type, and few significant differences were observed in PROMIS domains between developmental groups among on-treatment AYA survivors. In contrast, off-treatment emerging adults and young adults reported significantly higher symptoms and worse functioning compared to adolescents (all ps ≤ 0.003). CONCLUSIONS: AYAs diagnosed in different developmental stages, particularly among off-treatment survivors, experienced diverse constellations of symptoms and functioning, and developmental stage was a more critical predictor of HRQOL than cancer type. These results suggest that supportive care interventions developed for AYA cancer survivors must be tailored and flexible by developmental stage and treatment status.
OBJECTIVE: Our knowledge of symptom burden and functioning among adolescent and young adult (AYA; diagnosed ages 15-39) cancer survivors has been hindered by variability in health-related quality of life (HRQOL) measurement associated with developmental and disease heterogeneity among AYAs. We aimed to examine the variability in domain-specific aspects of HRQOL as a function of cancer type and developmental stage to clarify commonalities and differences using the NIH Patient-Reported Outcome Measurement Information System® . METHODS: Five hundred seventy-two AYAs were recruited by an online research panel using stratified sampling (treatment status: on vs. off; developmental stage: adolescents, emerging adults, young adults). Participants completed questionnaires that included sociodemographic characteristics, clinical history, and the adult version of the Patient-Reported Outcomes Measurement Information System® -29 (PROMIS-29). Generalized linear models were run for each HRQOL domain and included treatment status, developmental stage, and cancer type (hematologic vs. solid tumor) and their interactions as independent variables. RESULTS: There were no significant differences in any HRQOL domain by cancer type, and few significant differences were observed in PROMIS domains between developmental groups among on-treatment AYA survivors. In contrast, off-treatment emerging adults and young adults reported significantly higher symptoms and worse functioning compared to adolescents (all ps ≤ 0.003). CONCLUSIONS: AYAs diagnosed in different developmental stages, particularly among off-treatment survivors, experienced diverse constellations of symptoms and functioning, and developmental stage was a more critical predictor of HRQOL than cancer type. These results suggest that supportive care interventions developed for AYA cancer survivors must be tailored and flexible by developmental stage and treatment status.
Authors: Olga Husson; Judith B Prins; Suzanne E J Kaal; Simone Oerlemans; Wendy B Stevens; Bradley Zebrack; Winette T A van der Graaf; Lonneke V van de Poll-Franse Journal: Acta Oncol Date: 2017-01-12 Impact factor: 4.089
Authors: Eun Sook Lee; Myung Kyung Lee; Soo Hyun Kim; Jung Sil Ro; Han Sung Kang; Seok Won Kim; Keun Seok Lee; Young Ho Yun Journal: Ann Surg Date: 2011-01 Impact factor: 12.969
Authors: Joseph R Henderson; Elizabeth Kiernan; Jennifer L McNeer; Angie Mae Rodday; Katherine Spencer; Tara O Henderson; Susan K Parsons Journal: J Adolesc Young Adult Oncol Date: 2017-11-30 Impact factor: 2.223
Authors: Heydon K Kaddas; Samantha T Pannier; Karely Mann; Austin R Waters; Sara Salmon; Tomoko Tsukamoto; Echo L Warner; Brynn Fowler; Mark A Lewis; Douglas B Fair; Anne C Kirchhoff Journal: J Adolesc Young Adult Oncol Date: 2019-09-16 Impact factor: 2.223
Authors: Olga Husson; Bryce B Reeve; Anne-Sophie Darlington; Christabel K Cheung; Samantha Sodergren; Winette T A van der Graaf; John M Salsman Journal: J Natl Cancer Inst Date: 2022-04-11 Impact factor: 13.506
Authors: Karly M Murphy; Edith Chen; Edward H Ip; Abby R Rosenberg; Mallory A Snyder; John M Salsman Journal: Qual Life Res Date: 2022-08-13 Impact factor: 3.440
Authors: Suzanne C Danhauer; Mollie Canzona; Reginald D Tucker-Seeley; Bryce B Reeve; Chandylen L Nightingale; Dianna S Howard; Nicole Puccinelli-Ortega; Denisha Little-Greene; John M Salsman Journal: Psychooncology Date: 2021-11-05 Impact factor: 3.955
Authors: Suzanne E J Kaal; Emma K Lidington; Judith B Prins; Rosemarie Jansen; Eveliene Manten-Horst; Petra Servaes; Winette T A van der Graaf; Olga Husson Journal: J Clin Med Date: 2021-04-22 Impact factor: 4.241